Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring
The Oncologist · 17.01.2025 · 30 (1)
DOI: 10.1093/oncolo/oyae188 ↗Kurz gefasst
Klinische Studie in der Zeitschrift The Oncologist, online erschienen am 31.07.2024. Verfasst von Xinyu Gui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer …. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron Emission Tomography Computed Tomography, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Peking University.
Abstract (Originalsprache)
Background
Patients with breast cancer exhibit heterogeneity in the expression of the human epithelial growth factor receptor 2 (HER2). Clinically, re-biopsying recurrent or metastatic lesions presents substantial challenges. This study aimed to evaluate the efficacy of HER2-targeted PET/CT imaging in identifying HER2 expression in breast cancer lesions and monitoring therapeutic responses. Patients and Methods This exploratory analysis used data from a prospective study that included adult patients with breast cancer who underwent both Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT imaging at Beijing Cancer Hospital between June 2020 and July 2023 (NCT04547309).
Results
Fifty-nine participants, with a median age of 55 years, were analyzed. Lesions imaged with HER2-targeted PET/CT before anti-HER2 therapy exhibited higher SUVmax values than after therapy in HER2 immunohistochemistry (IHC) 3 + lesions (19.9, 95% CI: 15.7-25.3 vs 9.8, 95% CI: 5.6-14.7; P = .006). A significant positive correlation was observed between SUVmax on HER2-targeted PET/CT and IHC before therapy (P = .034), with higher SUVmax values noted in lesions with positive HER2 pathology compared to those with negative HER2 status (17.9 ± 13.2 vs 1.1 ± 0.3; P = .007). HER2 expression heterogeneity was confirmed both between primary and metastatic lesions (22.9%) and among different metastatic sites (26.7%) as assessed by HER2-targeted PET/CT. A superior therapeutic response correlated with higher pretreatment SUVmax values. The HER2-targeted PET/CT procedure was well-tolerated by all patients.
Conclusion
HER2-targeted PET/CT imaging offers a practical, non-invasive, and quantitative approach for assessing HER2 status in breast cancer patients, facilitating the optimization and personalization of therapeutic strategies by oncologists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, People's Republic of China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department…
ORCID-Profile: Xinyu Gui, Guohong Song
Förderung
- National Natural Science Foundation of China
- Peking University
Zitieren
APA
Gui, X., Liang, X., Guo, X., Yang, Z., & Song, G. (2025). Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring. The Oncologist, 30(1). https://doi.org/10.1093/oncolo/oyae188
Vancouver
Gui X, Liang X, Guo X, Yang Z, Song G. Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring. The Oncologist. 2025;30(1). doi:10.1093/oncolo/oyae188
BibTeX
@article{Gui2025,
author = {Gui, Xinyu and Liang, Xu and Guo, Xiaoyi and Yang, Zhi and Song, Guohong},
title = {Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {1},
doi = {10.1093/oncolo/oyae188}
}
EUVIMED